Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7760207 | 0.80 | IDO1 (0.44) | ALDH1A1KDM4EHPGDMEN1MAPT | |
| SCHEMBL26259958 | 0.76 | IDO1 (0.39) | ALDH1A1HSD17B10CYP1A2MAPK1IDO1 | |
| SCHEMBL14799704 | 0.76 | IDO1 (0.38) | ALDH1A1KDM4EHPGDMEN1MAPT | |
| SCHEMBL2543830 | 0.72 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDMEN1MAPT | |
| SCHEMBL26259972 | 0.72 | IDO1 (0.39) | MEN1MAPTKMT2AMCL1CYP1A2 | |
| SCHEMBL30291295 | 0.71 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDMEN1MAPT | |
| SCHEMBL2457144 | 0.69 | ESR1 (0.50) | ALDH1A1KDM4EMAPTCYP1A2CYP11B1 | |
| Ammonia Solution, Strong SCHEMBL28090479 | 0.69 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDMEN1MAPT | |
| SCHEMBL22124455 | 0.67 | KDM4E (0.41) | ALDH1A1KDM4EHPGDMEN1MAPT | |
| SCHEMBL17442214 | 0.66 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | claimed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | claimed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | claimed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-12-05 | — | — | US | disclosed |
| EP-2646025-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-05-02 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011095584-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| EP-0422134-A4 | 5-HT SELECTIVE AGENTS | — | 1992-05-06 | — | — | EP | disclosed |
| US-4605660-A | INHIBIT CONTRACTION OF SMOOTH MUSCLE | MERCK & CO., INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4605660-A | INHIBIT CONTRACTION OF SMOOTH MUSCLE | MERCK & CO., INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4605660-A | INHIBIT CONTRACTION OF SMOOTH MUSCLE | MERCK & CO., INC. (US) | 1986-08-12 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | OPRL1, OPRK1, OPRM1 | ALDH1A1 388/4885KDM4E 4055/4885HPGD 1280/4885 |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | SIGMAR1, SFN, TMEM97 | ALDH1A1 960/4885KDM4E 4767/4885HPGD 2901/4885 |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | SIGMAR1, OPRL1, OPRK1 | ALDH1A1 1184/4885KDM4E 3826/4885HPGD 2588/4885 |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | ALDH1A1 3677/4885KDM4E 3089/4885HPGD 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.